Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 7, 2022
- Accepted August 17, 2023
- Published online September 15, 2023.
Article Versions
- You are currently viewing a previous version of this article (September 15, 2023 - 07:31).
- View the most recent version of this article
Copyright & Usage
Copyright © 2023, Parenteral Drug Association
Author Information
- Patricia Parris1,19 (patricia.parris{at}pfizer.com),
- Geraldine Whelan2 (geraldine.b.whelan{at}gsk.com),
- Anders Burild3 (qabu{at}novonordisk.com),
- Jessica Whritenour4 (jessica.duffy-whritenour{at}pfizer.com),
- Uma Bruen5 (uma.bruen{at}organon.com),
- Joel Bercu6 (joel.bercu{at}gilead.com),
- Courtney Callis7 (courtney.callis{at}lilly.com),
- Martyn L. Chilton8 (martyn.chilton{at}lhasalimited.org),
- Jessica Graham9 (graham.jessica{at}gene.com),
- Esther Johann10 (esther.johann{at}merckgroup.com),
- Candice Johnson11 (cjohnson{at}leadscope.com),
- Troy Griffin12 (troy.griffin{at}tevapharm.com),
- Martin Kohan13 (martin.kohan{at}safebridge.com),
- Elizabeth A. Martin14 (elizabeth.martin{at}astrazeneca.com),
- Melisa Masuda-Herrera15 (melisa.masuda-herrera{at}gilead.com),
- Brad Stanard16 (bstanard{at}ultragenyx.com),
- Maureen T Cruz17 (maureen.cruz{at}faegredrinker.com) and
- Lee Nagao18 (lee.nagao{at}faegredrinker.com)
- 1 Pfizer Worldwide Research, Development and Medical, Sandwich, UK;
- 2 GlaxoSmithKline, Ware, UK;
- 3 Novo Nordisk A/S, Safety Sciences and Imaging, Malov, Denmark;
- 4 Pfizer Worldwide Research, Development and Medical, Groton, CT, USA;
- 5 Organon USA Inc., Jersey City, NJ, USA;
- 6 Gilead Sciences Inc., Foster City, CA, USA;
- 7 Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, USA;
- 8 Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK;
- 9 Genentech, Inc., South San Francisco, CA, USA;
- 10 Merck KGaA, Darmstadt, Germany;
- 11 Instem, 1393 Dublin Road, Columbus, Ohio USA;
- 12 Teva Branded Pharmaceutical Products R&D, West Chester, PA, USA;
- 13 formerly of Global Sustainability, AstraZeneca, Cambridge, UK;
- 14 Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK;
- 15 Gilead Sciences;
- 16 Ultragenyx Pharmaceutical Inc., Novato, CA, USA;
- 17 Faegre Drinker Biddle & Reath LLP;
- 18 Faegre Drinker Biddle & Reath
- ↵* Corresponding author; email: patricia.parris{at}pfizer.com
